ACAD receives BTD in dementia-related psychosis; Initiates DRP phase 3 trial; Phase 2 SERENE trial discontinued.
Drug maker Omeros Corporation (NASDAQ:OMER) announced that it entered into a settlement agreement with Par Pharmaceutical and its subsidiary Par Sterile Products, resolving …
TEVA needs a long-term solution after MYL’s generic Copaxone approval; VRX works on its debt problem.
Amyris, Inc. (NASDAQ:AMRS) announced that it has entered into a product development and production agreement for a new class of human nutrition ingredients …
Celsion strikes iron while its hot to raise $15.6 million; Catabasis slows rate of DMD decline in OLE trial.
These two pharma stocks all have upside of over 100% say top Wall Street analysts.
These stocks to buy have significant support from top analysts.
In a research report issued Wednesday, Baird’s top analyst Colin Sebastian rebuked Citron for its short report on Shopify Inc (US) (NYSE:SHOP), and reiterated his Outperform rating …
Analysts weigh in with confidence on two biotech stocks blasting through the roof this week.
Shopify is a completely illegal get-rich-quick scheme (with a good software platform).